# A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

> **NCT01600976** · PHASE1 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** telaprevir

## Key facts

- **NCT ID:** NCT01600976
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01600976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01600976, "A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01600976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*